Belgian value-added medicines specialist Hyloris Pharmaceuticals has announced yet another licensing deal for its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg intravenous analgesic, extending a deal initially struck with Pharma Bavaria International in 2020 for Central America to cover Latin America and the Caribbean.
Hyloris Pushes Into South America With Maxigesic IV
Extends Existing Alliance With Pharma Bavaria To Cover 17 Countries
Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.
